A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) who have Failed Erythropoietin Stimulating Agents (ESA)
The purpose of the study is to find a safe dose and evaluate the effectiveness of the study drug, canakinumab, in combination with a commonly used therapy, darbepoetin alfa.
Primary Objective (Phase 1b) To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of canakinumab as determined by DLTs. Primary Objective (Phase 2) To determine the rate of hematologic improvement-erythroid (HI-E), defined as red blood cell transfusion independence (RBC-TI) of at least 8 weeks in transfusion dependent patients or a mean Hgb increase of 1.5g/dL above baseline sustained for at least 8 weeks in non-transfusion dependent patients. Secondary Objectives (Phase 1b and 2) 1. To determine the duration of HI-E response 2. To determine the degree of reduction in red blood cell transfusions 3. To determine the overall response rate (ORR) (IWG 2006) 4. To determine the duration of response by IWG 2006 criteria 5. To determine the progression free survival (PFS) 6. To determine the effect on patient s symptoms and quality of life (QoL) 7. To determine whether recurrent genetic mutations are predictive of response 8. To characterize in vivo IL-1 inhibition with canakinumab 9. To evaluate the relationship between changes in innate immune and pyroptosis biomarker indices with response to treatment. 10. To determine the prevalence of infections associated with canakinumab therapy in MDS patients.
Canakinumab (); Darbepoetin alfa ()
- > Adequate organ function as defined by laboratory values per protocol
- Documented diagnosis of MDS by World Health Organization (WHO) criteria, further meeting the following criteria according to disease risk classification
- Patients must be transfusion dependent, defined as requirement for transfusion of at least 3 units of Packed Red Blood cells (PRBCs) 16 weeks for a Hgb> Eastern Cooperative Oncology Group (ECOG) Performance Status > Women of child bearing potential must have negative urine or serum pregnancy test within 28 days prior to start of study drug.
- Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence; tubal ligation, partner's vasectomy) prior to Cycle 1 Day 1 and for the duration of study participation
- > Use of chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment.
- Previous treatment with a hypomethylating agent (such as azacitidine, decitabine or investigational hypomethylating agent).
- Use of concurrent growth factors such as G-CSF, GM-CSF, or thrombopoietin mimetics during study except in cases of febrile neutropenia, where G-CSF can be used for short term. Growth factors must be stopped two weeks prior to study.
- Patient has any of the following cardiac abnormalities: (a) Uncontrolled, symptomatic congestive heart failure as designated by the treating physician (b) Myocardial infarction ≤ 6 months prior to enrollment (c) Unstable angina pectoris as designated by the treating physician (d) Serious uncontrolled cardiac arrhythmia as designated by the treating physician. (e) Uncontrolled hypertension as designated by the treating physician
- Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with Hepatitis B or Hepatitis C.
- Active tuberculosis (Tb) infection or documented, untreated latent Tb infection (all patients should undergo Tb risk evaluation prior to enrollment with Tb screening performed as per local guidelines,
- Active, uncontrolled infection at the time of enrollment, except in cases of localized infections that are unlikely to lead to a systemic infection such as onychomycoses or dental caries. Patients with new fever (> 38.0 C) or respiratory symptoms are required to undergo laboratory screening for COVID-19
- Have undergone prior allo-HSCT for the treatment of MDS, or other hematologic disorder, or prior solid organ transplant.
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
- Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- Patients with a condition requiring systemic treatment with corticosteroids within 14 days of study drug administration (i.e. prednisone at doses of >10mg). Inhaled or topical steroids and adrenal/pituitary replacement doses >10mg daily prednisone equivalents are permitted.
- Patients undergoing concurrent treatment with agents targeting tumor necrosis factor alpha (TNF) or IL-1 within 28 days of study enrollment.
- Patients who have received a live-virus vaccine within 30 days before study drug administration (patients should not be treated with live-virus vaccine while undergoing therapy).
- History of allergy or hypersensitivity to either darbepoetin alfa or the study drug or its components.
- Women of child bearing potential who are pregnant or breastfeeding.
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.